OriCell Therapeutics

Focus: OriCell Therapeutics is a China-based biotech company founded in 2023 specializing in tumor immunotherapy, bispecific antibodies, and CAR-T cell therapies. The company is in Series C+ funding stage, positioning itself as a clinical-stage player in oncology and cell therapy.

Oncology Cell Therapy

Profile data last refreshed 20h ago · AI intelligence enriched 1w ago

Funding Stage

SERIES C +

Open Jobs

About OriCell Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow OriCell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

OriC902

HCC

Phase 1

Clinical Trials (1)

NCT06891742Phase I Study of OriC902 in Treatment of Advanced HCC

Phase 1

Help build intelligence for OriCell Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage company (founded 2023) with advanced Series C+ funding backing, offering high equity upside potential for founding-era employees
Focused on high-value oncology modalities (CAR-T, bispecific antibodies, tumor immunotherapy) with significant unmet medical need
Based in Shanghai with access to China's large patient population and emerging biotech ecosystem

Watch Out For

Zero clinical trial data visible (0 Phase 1/2/3 programs reported) raises questions about pipeline maturity and execution track record despite 2023 founding
No active job openings currently listed, suggesting either post-hiring freeze or non-disclosure of open roles on major platforms
Founded only recently (2023) with limited public data on financial stability, leadership track record, or scientific publications

Generated by Claude from OriCell Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

OriV508 Injection

Multiple Myeloma (MM)

Phase 1

Clinical Trials (1)

NCT07101705An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

Phase 1

GPRC5D-CAR-T

Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT05016778A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Phase 1

OriCAR-017

Neoplasms, Plasma Cell

Phase 1

Clinical Trials (1)

NCT06271252A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Phase 1

OriCAR-017

Relapsed and/or Refractory Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT06182696OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Phase 1/2

Ori-C101

Hepatocellular Carcinoma

Phase 1/2

Clinical Trials (1)

NCT05652920Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Phase 1/2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 6 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

5 pipeline

Marketed

Pipeline